A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study
Carlo Signorelli,Maria Alessandra Calegari,Annunziato Anghelone,Alessandro Passardi,Giovanni Luca Frassineti,Alessandro Bittoni,Jessica Lucchetti,Lorenzo Angotti,Emanuela Di Giacomo,Ina Valeria Zurlo,Cristina Morelli,Emanuela Dell'Aquila,Adele Artemi,Donatello Gemma,Domenico Cristiano Corsi,Alessandra Emiliani,Marta Ribelli,Federica Mazzuca,Giulia Arrivi,Federica Zoratto,Mario Giovanni Chilelli,Marta Schirripa,Maria Grazia Morandi,Fiorenza Santamaria,Manuela Dettori,Antonella Cosimati,Rosa Saltarelli,Alessandro Minelli,Emanuela Lucci-Cordisco,Michele Basso
DOI: https://doi.org/10.3390/curroncol31120574
2024-12-06
Current Oncology
Abstract:Background: There is ongoing discussion around the optimal course of treatment for metastatic colorectal cancer (mCRC) following the second line. Trifluridine/tipiracil (T) and regorafenib (R) have been the mainstay of therapy in this situation, as they both increased overall survival (OS) in comparison to a placebo. Despite the paucity of evidence, therapy rechallenge is also recognized as an option for practical use. In the third-line scenario of mCRC, we planned to investigate the survival outcomes using (T) and (R), both with and without prior rechallenge treatment. Materials and methods: Between 2012 and 2023, we examined the medical records of 1156 patients with refractory mCRC who were enrolled in the multicenter retrospective ReTrITA study. We then separated the patients into two cohorts based on the rechallenge therapy that was given before regorafenib and/or trifluridine/tipiracil at 17 Italian centres. Results: A total of 981 patients underwent T and/or R therapy, while 175 patients had therapy rechallenge before T and/or R. The median overall survival (mOS) for patients treated with T/R and R/T sequences in the rechallenge therapy cohort was 14.5 months and 17.6 months, respectively (p = 0.1955). A statistically significant survival benefit was observed in patients who received monotheraphy with R (mOS: 6 months) compared to the T group (mOS: 4.2 months) (p = 0.0332). In the same cohort, a median progression-free survival (mPFS) benefit was demonstrated in favour of the R/T group (11.3 months) vs. 9 months of the reverse sequence (p = 0.4004). In the no-rechallenge cohort, the mOS was statistically longer in the R/T sequence than in the T/R sequence (16.2 months vs. 12.3 months, respectively; p = 0.0014). In terms of the mPFS, we saw the same significant result for the adoption of R/T treatment (11.5 months vs. 8.4 months, respectively; p < 0.0001). The two monotherapy groups did not reveal any significant differences. Conclusions: This study suggests that rechallenge therapy may improve survival rates in the third-line treatment of mCRC, particularly if it is administered before sequential R/T treatment. This could allow for the extension of mCRC treatment choices until prospective studies are finished or randomised trials are performed.
oncology